News & Events about Foghorn Therapeutics Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26, 2023...
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at Cowens 43rd Annual...
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to ...
Research analysts at BMO Capital Markets began coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set an outperform rating and a $20.00 price target on the stock. BMO Capital Markets’...